Table 2 Patient characteristics—metastatic tumours

From: Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Category Subcategory mCRC (n = 237) NET (n = 58) Breast (n = 47) Pancreatic (n = 32) Melanoma (n = 32) Other liver metastases (n = 79)a All (n = 485)
ECOG status 0–fully active 140 (59.1%) 38 (65.5%) 29 (61.7%) 20 (62.5%) 15 (46.9%) 41 (51.9%) 283 (58.4%)
1–restricted 75 (31.6%) 14 (24.1%) 16 (34.0%) 8 (25.0%) 14 (43.8%) 32 (40.5%) 159 (32.8%)
2 or higher 18 (7.6%) 5 (8.6%) 2 (4.3%) 3 (9.4%) 1 (3.1%) 6 (7.6%) 35 (7.2%)
Missingb 4 (1.7%) 1 (1.7%) 1 (3.1%) 2 (6.3%) 8 (1.6%)
Extra-hepatic disease No 139 (58.6%) 25 (43.1%) 17 (36.2%) 17 (53.1%) 25 (78.1%) 33 (41.8%) 256 (52.8%)
Yes 98 (41.4%) 33 (56.9%) 30 (63.8%) 15 (46.9%) 7 (21.9%) 46 (58.2%) 229 (47.2%)
Ascites No 228 (96.2%) 54 (93.1%) 44 (93.6%) 29 (90.6%) 31 (96.9%) 75 (94.9%) 461 (95.1%)
Yes 9 (3.8%) 4 (6.9%) 3 (6.4%) 3 (9.4%) 1 (3.1%) 4 (5.1%) 24 (4.9%)
Cirrhosis No 235 (99.2%) 58 (100%) 45 (95.7%) 32 (100%) 32 (100%) 77 (97.5%) 479 (98.8%)
Yes 2 (0.8%) 2 (4.3%) 2 (2.5%) 6 (1.2%)
Location of liver tumours Bilobar 158 (66.7%) 51 (87.9%) 37 (78.7%) 23 (71.9%) 32 (100%) 56 (70.9%) 357 (73.6%)
Left only 23 (9.7%) 4 (8.5%) 1 (3.1%) 5 (6.3%) 33 (6.8%)
Right only 55 (23.2%) 7 (12.1%) 6 (12.8%) 8 (25.0%) 18 (22.8%) 94 (19.4%)
Missing 1 (0.4%) 1 (0.2%)
Number of liver tumours 1 21 (8.9%) 2 (3.4%) 7 (14.9%) 1 (3.1%) 3 (9.4%) 8 (10.1%) 42 (8.7%)
2–5 52 (21.9%) 9 (15.5%) 4 (8.5%) 6 (18.8%) 5 (15.6%) 12 (15.2%) 88 (18.1%)
6–9 25 (10.5%) 3 (6.4%) 1 (3.1%) 2 (6.3%) 9 (11.4%) 40 (8.2%)
10 or more 58 (24.5%) 14 (24.1%) 7 (14.9%) 10 (31.3%) 15 (46.9%) 18 (22.8%) 122 (25.2%)
Uncountable 81 (34.2%) 33 (56.9%) 26 (55.3%) 14 (43.8%) 7 (21.9%) 32 (40.5%) 193 (39.7%)
Portal vein Patent 234 (98.7%) 58 (100%) 43 (91.5%) 32 (100%) 30 (93.8%) 75 (94.9%) 472 (97.3%)
Segmental thrombosis 3 (1.3%) 3 (6.4%) 1 (3.1%) 2 (2.5%) 9 (1.9%)
Lobar thrombosis 1 (3.1%) 1 (1.3%) 2 (0.4%)
Main thrombosis 1 (2.1%) 1 (1.3%) 2 (0.4%)
Total tumour to liver percentage Median 8.9% 20.8% 7.8% 6.6% 10.7% 10.9% 10.5%
Q1, Q3 3.8%, 18.3% 8.5%, 40.0% 4.0%, 18.6% 3.8%, 14.0% 5.0%, 18.8% 4.0%, 25.6% 4.5%, 21.8%
Missing 40 (18.9%) 17 (29.3%) 18 (38.3%) 6 (24.0%) 12 (37.5%) 12 (15.2%) 105 (21.6%)